Intriguingly, GPER signaling shows significant crosstalk with the PAM pathways in various disease models, including BC,113, 114, 115, 116, 117, 118 suggesting that the combination of targeting GPER and PAM inhibitors might constitute an effective treatment option, which can be achieved using convenient and inexpensive immunohistochemical methods. Here, GPER1 is linked to breast cancer.